| Symbol | LITS |
|---|
| Name | MEI PHARMA, INC. |
|---|
| Sector | HEALTH CARE |
|---|
| Region | North America |
|---|
| Industry | Biotechnology: Pharmaceutical Preparations |
|---|
| Address | 11455 EL CAMINO REAL,SUITE 250, SAN DIEGO, California, 92130, United States |
|---|
| Telephone | +1 858 369-7100 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | https://www.meipharma.com |
|---|
| Incorporation | UNDEFINED |
|---|
| Incorporated On | — |
|---|
| Employees | — |
|---|
| Fiscal Year | — |
|---|
| Public Since | — |
|---|
| Exchanges | NASDAQ |
|---|
| Auditor | — |
|---|
| Audit Status | NOT PROVIDED |
|---|
| Reporting Status | — |
|---|
| CIK | 0001262104 |
|---|
| Description | MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The companys clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkins lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Additional info from NASDAQ:
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The companys clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkins lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States. |
|---|
2026-05-13 12:35
(70% Positive) MEI PHARMA, INC. (LITS) Reports Q2 2026 Financial Results
Read more
2026-05-13 12:30
Lite Strategy Reports Fiscal 2026 Third Quarter Results
Read more
| Trial ID |
Title |
Phase |
Indication |
Status |
Start Date |
Completion Date |
Source |
|
NCT05824559
|
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer |
Phase1
|
Colorectal Cancer |
Terminated
|
2023-08-07 |
2024-07-23 |
ClinicalTrials.gov
|
|
NCT05604417
|
Zandelisib + Tazemetostat in R/R Follicular Lymphoma |
Phase1
|
Relapsed Follicular Lymphoma |
Withdrawn
|
2023-01-01 |
2026-12-01 |
ClinicalTrials.gov
|
|
NCT05209308
|
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
Phase2
|
CLL |
Withdrawn
|
2022-11-22 |
2023-03-15 |
ClinicalTrials.gov
|
|
NCT04745832
|
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients … |
Phase3
|
Follicular Lymphoma (FL) |
Terminated
|
2021-08-13 |
2023-03-20 |
ClinicalTrials.gov
|
|
NCT03768505
|
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymph… |
Phase2
|
Follicular Lymphoma (FL) |
Terminated
|
2019-06-25 |
2023-03-24 |
ClinicalTrials.gov
|
|
NCT03547115
|
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With … |
Phase1
|
Follicular Lymphoma (FL) |
Terminated
|
2018-05-31 |
2024-07-24 |
ClinicalTrials.gov
|
|
NCT02914938
|
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lympho… |
Phase1
|
Chronic Lymphocytic Leukemia (CLL) |
Terminated
|
2016-10-01 |
2023-03-29 |
ClinicalTrials.gov
|
|
NCT02521389
|
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Va… |
Phase1
|
Malignancies |
Completed
|
2015-06-29 |
2017-02-24 |
ClinicalTrials.gov
|
|
NCT02100007
|
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors |
Phase1
|
Solid Tumors |
Terminated
|
2014-04-01 |
2016-04-01 |
ClinicalTrials.gov
|
|
NCT01544322
|
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent… |
Phase1
|
Solid Tumors |
Completed
|
2012-05-01 |
2014-08-01 |
ClinicalTrials.gov
|
|
NCT01401868
|
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Sing… |
Phase1
|
Solid Tumors |
Completed
|
2011-09-01 |
2013-01-01 |
ClinicalTrials.gov
|
|
NCT00557037
|
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Pros… |
Phase2
|
Prostate Cancer |
Completed
|
2007-11-01 |
2009-11-01 |
ClinicalTrials.gov
|
|
NCT00382811
|
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With a… |
Phase3
|
Fallopian Tube Cancer |
Completed
|
2006-10-01 |
2011-04-01 |
ClinicalTrials.gov
|
|
NCT00091377
|
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recur… |
Phase1
|
Fallopian Tube Cancer |
Completed
|
2004-08-01 |
2008-03-01 |
ClinicalTrials.gov
|
Total clinical trials: 14
| Product Name |
Type |
Development Stage |
Therapeutic Area |
Study Status |
Trial ID |
|
ME-143
|
Other
|
Phase PHASE1
|
Solid Tumors |
COMPLETED
|
NCT01401868
|
|
ME-344
|
Other
|
Phase PHASE1
|
Solid Tumors |
COMPLETED
|
NCT01544322
|
|
PWT-143
|
Other
|
Phase PHASE1
|
Malignancies |
COMPLETED
|
NCT02521389
|
|
Topotecan
|
Other
|
Phase PHASE1
|
Solid Tumors |
TERMINATED
|
NCT02100007
|
|
ME-344
|
Other
|
Phase PHASE1
|
Solid Tumors |
TERMINATED
|
NCT02100007
|
|
Venetoclax
|
Other
|
Phase PHASE2
|
CLL |
WITHDRAWN
|
NCT05209308
|
|
Rituximab
|
Other
|
Phase PHASE2
|
CLL |
WITHDRAWN
|
NCT05209308
|
|
Zandelisib
|
Other
|
Phase PHASE2
|
CLL |
WITHDRAWN
|
NCT05209308
|
|
Zanubrutinib
|
Other
|
Phase PHASE1
|
Chronic Lymphocytic Leukemia (CLL) |
TERMINATED
|
NCT02914938
|
|
Rituximab
|
Other
|
Phase PHASE1
|
Chronic Lymphocytic Leukemia (CLL) |
TERMINATED
|
NCT02914938
|
|
ME-401
|
Other
|
Phase PHASE1
|
Chronic Lymphocytic Leukemia (CLL) |
TERMINATED
|
NCT02914938
|
|
Zandelisib
|
Other
|
Phase PHASE1
|
Relapsed Follicular Lymphoma |
WITHDRAWN
|
NCT05604417
|
|
TAZEMETOSTAT
|
Other
|
Phase PHASE1
|
Relapsed Follicular Lymphoma |
WITHDRAWN
|
NCT05604417
|
|
CHOP
|
Other
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Bendamustine
|
Other
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Rituximab
|
Other
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Zandelisib
|
Other
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Bevacizumab
|
Other
|
Phase PHASE1
|
Colorectal Cancer |
TERMINATED
|
NCT05824559
|
|
ME-344
|
Other
|
Phase PHASE1
|
Colorectal Cancer |
TERMINATED
|
NCT05824559
|
|
Zandelisib (ME-401)
|
Other
|
Phase PHASE2
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03768505
|
|
voruciclib and venetoclax
|
Other
|
Phase PHASE1
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03547115
|
|
voruciclib monotherapy
|
Drug
|
Phase PHASE1
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03547115
|
|
Bevacizumab
|
DRUG
|
Phase PHASE1
|
Colorectal Cancer |
TERMINATED
|
NCT05824559
|
|
TAZEMETOSTAT
|
DRUG
|
Phase PHASE1
|
Relapsed Follicular Lymphoma |
WITHDRAWN
|
NCT05604417
|
|
Venetoclax
|
DRUG
|
Phase PHASE2
|
CLL |
WITHDRAWN
|
NCT05209308
|
|
CHOP
|
DRUG
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Bendamustine
|
DRUG
|
Phase PHASE3
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT04745832
|
|
Zandelisib
|
DRUG
|
Phase PHASE1
|
Relapsed Follicular Lymphoma |
WITHDRAWN
|
NCT05604417
|
|
Zandelisib (ME-401)
|
DRUG
|
Phase PHASE2
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03768505
|
|
voruciclib and venetoclax
|
DRUG
|
Phase PHASE1
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03547115
|
|
voruciclib monotherapy
|
DRUG
|
Phase PHASE1
|
Follicular Lymphoma (FL) |
TERMINATED
|
NCT03547115
|
|
Zanubrutinib
|
DRUG
|
Phase PHASE1
|
Chronic Lymphocytic Leukemia (CLL) |
TERMINATED
|
NCT02914938
|
|
Rituximab
|
DRUG
|
Phase PHASE2
|
CLL |
WITHDRAWN
|
NCT05209308
|
|
ME-401
|
DRUG
|
Phase PHASE1
|
Chronic Lymphocytic Leukemia (CLL) |
TERMINATED
|
NCT02914938
|
|
PWT-143
|
DRUG
|
Phase PHASE1
|
Malignancies |
COMPLETED
|
NCT02521389
|
|
ME-143
|
DRUG
|
Phase PHASE1
|
Solid Tumors |
COMPLETED
|
NCT01401868
|
|
Topotecan
|
DRUG
|
Phase PHASE1
|
Solid Tumors |
TERMINATED
|
NCT02100007
|
|
ME-344
|
DRUG
|
Phase PHASE1
|
Colorectal Cancer |
TERMINATED
|
NCT05824559
|
|
Phenoxodiol
|
DRUG
|
Phase PHASE2
|
Prostate Cancer |
COMPLETED
|
NCT00557037
|
|
placebo
|
DRUG
|
Phase PHASE3
|
Fallopian Tube Cancer |
COMPLETED
|
NCT00382811
|
|
carboplatin
|
DRUG
|
Phase PHASE3
|
Fallopian Tube Cancer |
COMPLETED
|
NCT00382811
|
|
phenoxodiol
|
DRUG
|
Phase PHASE3
|
Fallopian Tube Cancer |
COMPLETED
|
NCT00382811
|
|
paclitaxel
|
DRUG
|
Phase PHASE1
|
Fallopian Tube Cancer |
COMPLETED
|
NCT00091377
|
|
cisplatin
|
DRUG
|
Phase PHASE1
|
Fallopian Tube Cancer |
COMPLETED
|
NCT00091377
|
Total products: 44